Efferon is a biotech company developing hemoadsorption devices designed to remove endotoxins and inflammatory mediators from the bloodstream for the treatment of sepsis, septic shock and other inflammation-related conditions.
Biotech company Efferon has raised €2.5 million in a seed funding round led by private investors from the DACH region to support the European commercial expansion of Efferon LPS, its hemoadsorption device approved for the treatment of sepsis and septic shock.
Efferon develops multimodal hemoadsorption therapeutic devices designed to remove endotoxins and inflammatory mediators directly from the bloodstream. The company’s product portfolio includes Efferon LPS, a hemoadsorption cartridge combining endotoxin and cytokine adsorption, and Efferon NEO, a version developed for pediatric use.
Use of Efferon devices can help reduce ICU treatment costs by supporting faster stabilisation of septic shock and reducing time spent on mechanical ventilation and intensive care treatment, according to the company.
Systemic inflammation plays a role not only in acute critical illness, but also across a range of chronic and age-related diseases. Efferon says its hemoadsorption platform is designed to support future applications beyond intensive care and sepsis treatment.
According to Dima Romashin, CEO and co-founder of Efferon, sepsis causes more than 11 million deaths annually worldwide, yet continues to receive significantly less research attention and funding than other major diseases such as cancer.
We’re not just bringing a product to market – we’re fighting to put sepsis where it belongs: at the top of the world’s medical agenda.
Efferon recently received CE MDR certification for Efferon NEO, making it the first hemoadsorption device in Europe approved for neonatal and pediatric patients with sepsis and septic shock. The approval was supported by results from the multicentre LASSO NEO study, which evaluated targeted endotoxin and cytokine removal in patients aged between one month and 18 years.
The company says its technology has already been used in more than 25,000 treatments across over 40 countries, including Germany, the United Kingdom, Australia and Saudi Arabia.
The new funding will support the construction of a new EU production facility for Efferon LPS and the expansion of the company’s manufacturing capacity to meet growing demand for its blood purification therapy for sepsis and septic shock.